Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased in Japan due to steady demand for medical equipment and strengthened sales activities, and overseas due to new customer acquisition and new product launches in Europe, as well as customer expansion in the United States and India. Sales in China declined following the reversal of the prior fiscal year's spot sales. Although the increase in net sales contributed to operating profit, expenses included a deterioration in the product mix, higher cost ratios for certain products due to increased OEM production, and SG&A expenses such as academic conference exhibition costs, certification costs in various countries, and costs associated with maintaining the listed-company framework.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥10,947 million (YoY +6.3%) |
| Operating profit | ¥5,858 million (YoY +1.3%) |
| Ordinary income | ¥5,903 million (YoY +2.4%) |
| Profit attributable to owners of the parent | ¥3,895 million (YoY +2.8%) |
| Net income per share | ¥97.38 |
| Operating Margin | 53.5% |
| Equity ratio | End of the current fiscal period 93.2 / End of previous period 92.4 |
| Total assets | ¥21,996 million |
| Net assets | ¥20,504 million |
| Cash flows from operating activities | ¥3,870 million |
| Cash flows from investing activities | ¥-237 million |
| Cash flows from financing activities | ¥-1,738 million |
| Cash and cash equivalents at end of period | ¥13,414 million |
| Full-year earnings forecast | Net Sales ¥11,346 million (YoY +3.6%) / Operating profit ¥6,115 million (YoY +4.4%) / Ordinary income ¥6,137 million (YoY +4.0%) / Profit attributable to owners of the parent ¥4,059 million (YoY +4.2%) |
| Annual Dividend Forecast | ¥41 → ¥41（0.0%） |
| Payout ratio | 40.4% |
| Regional sales | Region Japan / Net Sales ¥3,660 million / yoy_pct ¥4.7 million, Region Overseas expansion / Net Sales ¥7,287 million / yoy_pct ¥7.1 million, Region Europe / Net Sales ¥3,990 million / yoy_pct ¥15.7 million, Region United States / Net Sales ¥1,120 million / yoy_pct ¥9.6 million, Region China / Net Sales ¥672 million / yoy_pct ¥-22.5 million, Region India / Net Sales ¥593 million / yoy_pct ¥26.9 million, Region Other / Net Sales ¥909 million / yoy_pct ¥-8.9 million |
| Depreciation and amortization | ¥190 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥0 million / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 40,000,000 Shares |
| Treasury Shares at Period-End | 0 Shares |
| Factors Behind Changes in Business Performance | Net sales increased in Japan due to steady demand for medical equipment and strengthened sales activities, and overseas due to new customer acquisition and new product launches in Europe, as well as customer expansion in the United States and India. Sales in China declined following the reversal of the prior fiscal year's spot sales. Although the increase in net sales contributed to operating profit, expenses included a deterioration in the product mix, higher cost ratios for certain products due to increased OEM production, and SG&A expenses such as academic conference exhibition costs, certification costs in various countries, and costs associated with maintaining the listed-company framework. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, the company strengthened its sales activities by providing thorough follow-up to customers in addition to benefiting from steady demand for medical equipment. Overseas, it acquired new customers and launched new products in Europe, while expanding its customer base in the United States and India. On the earnings side, the increase in net sales contributed positively, while expenses included a deterioration in the product mix, higher cost ratios for certain products due to increased OEM production, and SG&A expenses such as exhibition costs for academic conferences and costs of obtaining certifications in various countries.